ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
Abstract Background ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic e...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-5948-y |
| _version_ | 1818289150496866304 |
|---|---|
| author | Shuguang Xu Wenxian Wang Chunwei Xu Xingliang Li Junhui Ye Youcai Zhu Ting Ge |
| author_facet | Shuguang Xu Wenxian Wang Chunwei Xu Xingliang Li Junhui Ye Youcai Zhu Ting Ge |
| author_sort | Shuguang Xu |
| collection | DOAJ |
| description | Abstract Background ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic effect against ROS1-rearranged NSCLC. Next-generation sequencing (NGS) technology represents a novel tool for ROS1 detection that covers many fusion genes. Case presentation A 55-year-old female with EGFR mutation (L858R) was diagnosed with lung adenocarcinoma, who was responsive to first-generation EGFR-tyrosine kinase inhibitor (TKI). Afterwards, she developed acquired resistance accompanied with a ROS1 rearrangement. A NGS assay showed that the tumor had a novel ROS1-ADGRG6 rearrangement generated by the fusion of exons of 1–33 of ROS1 on chr6: q22.1 to exons of 2–26 of ADGRG6 on chr6: q24.2. The patient was obviously responsive to crizotinib. Conclusion We firstly identified ROS1-ADGRG6 fusion variant in NSCLC by NGS, which should be considered in further ROS1 detecting assays. |
| first_indexed | 2024-12-13T02:07:42Z |
| format | Article |
| id | doaj.art-4ed1082c011a41c48ec75a0bfd9ae621 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-13T02:07:42Z |
| publishDate | 2019-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-4ed1082c011a41c48ec75a0bfd9ae6212022-12-22T00:03:05ZengBMCBMC Cancer1471-24072019-08-011911410.1186/s12885-019-5948-yROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinibShuguang Xu0Wenxian Wang1Chunwei Xu2Xingliang Li3Junhui Ye4Youcai Zhu5Ting Ge6Department of Respiratory Medicine, Ningbo Medical Center Lihuili Eastern HospitalDepartment of Chemotherapy, Zhejiang Cancer HospitalDepartment of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer HospitalDepartment of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun HospitalDepartment of Respiratory, Sanmen People’s Hospital of ZhejiangDepartment of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun HospitalDepartment of Respiratory, Ningbo Medical Center Lihuili HospitalAbstract Background ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic effect against ROS1-rearranged NSCLC. Next-generation sequencing (NGS) technology represents a novel tool for ROS1 detection that covers many fusion genes. Case presentation A 55-year-old female with EGFR mutation (L858R) was diagnosed with lung adenocarcinoma, who was responsive to first-generation EGFR-tyrosine kinase inhibitor (TKI). Afterwards, she developed acquired resistance accompanied with a ROS1 rearrangement. A NGS assay showed that the tumor had a novel ROS1-ADGRG6 rearrangement generated by the fusion of exons of 1–33 of ROS1 on chr6: q22.1 to exons of 2–26 of ADGRG6 on chr6: q24.2. The patient was obviously responsive to crizotinib. Conclusion We firstly identified ROS1-ADGRG6 fusion variant in NSCLC by NGS, which should be considered in further ROS1 detecting assays.http://link.springer.com/article/10.1186/s12885-019-5948-yLung adenocarcinomaNGSROS1 rearrangement |
| spellingShingle | Shuguang Xu Wenxian Wang Chunwei Xu Xingliang Li Junhui Ye Youcai Zhu Ting Ge ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib BMC Cancer Lung adenocarcinoma NGS ROS1 rearrangement |
| title | ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib |
| title_full | ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib |
| title_fullStr | ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib |
| title_full_unstemmed | ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib |
| title_short | ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib |
| title_sort | ros1 adgrg6 a case report of a novel ros1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib |
| topic | Lung adenocarcinoma NGS ROS1 rearrangement |
| url | http://link.springer.com/article/10.1186/s12885-019-5948-y |
| work_keys_str_mv | AT shuguangxu ros1adgrg6acasereportofanovelros1oncogenicfusionvariantinlungadenocarcinomaandtheresponsetocrizotinib AT wenxianwang ros1adgrg6acasereportofanovelros1oncogenicfusionvariantinlungadenocarcinomaandtheresponsetocrizotinib AT chunweixu ros1adgrg6acasereportofanovelros1oncogenicfusionvariantinlungadenocarcinomaandtheresponsetocrizotinib AT xingliangli ros1adgrg6acasereportofanovelros1oncogenicfusionvariantinlungadenocarcinomaandtheresponsetocrizotinib AT junhuiye ros1adgrg6acasereportofanovelros1oncogenicfusionvariantinlungadenocarcinomaandtheresponsetocrizotinib AT youcaizhu ros1adgrg6acasereportofanovelros1oncogenicfusionvariantinlungadenocarcinomaandtheresponsetocrizotinib AT tingge ros1adgrg6acasereportofanovelros1oncogenicfusionvariantinlungadenocarcinomaandtheresponsetocrizotinib |